Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 32 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05027386 |
| Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. |
| completed |
| Phase 1 / Phase 2 |
| 125 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06914128 | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 450 | BayerINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT07231211 | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 258 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07260708 | Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers | recruiting | Phase 1 | 42 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07570017 | A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 42 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 39 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04947241 | Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC | active not recruiting | Phase 1 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05320809 | Study of 3D189 in Patients With Hematologic Malignancies | completed | Phase 1 | 16 | 3D MedicinesINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT07038044 | Safety and Efficacy of an Arginine-Restricted Diet in Patients With Solid Tumors | completed | Phase 1 | 25 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07556822 | Phase I Study of HRS-3005 in B-cell Malignancies | recruiting | Phase 1 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07635277 | Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury(AKK-RIS) | recruiting | Phase 1 | 40 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVIV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07703163 | Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer(SGLT2SOLID) | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVSV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809126 | A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies | not yet recruiting | Phase 1 | 30 | Nanjing Miracle Biotechnology Co., Ltd.OTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809139 | A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies | not yet recruiting | Phase 1 | 30 | Nanjing Miracle Biotechnology Co., Ltd.OTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810933 | A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 330 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811037 | A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 332 | Beijing Sungen Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811076 | Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer(SG-RCT) | not yet recruiting | Phase 1 / Phase 2 | 140 | Xuelei Ma MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors(PIKASSO-01) | recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer(MoonROSE) | recruiting | Phase 1 / Phase 2 | 285 | Genentech, Inc.INDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT07367529 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | recruiting | Phase 1 / Phase 2 | 465 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer | recruiting | Phase 1 | 118 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07750132 | Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 72 | Beijing StarMab Biomed Technology LtdINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806175 | A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 486 | Rongchang Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05688605 | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 18 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06076291 | An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors(CSG-1827-101) | completed | Phase 1 | 19 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06167486 | SG2918 For Advanced Malignant Tumors | completed | Phase 1 | 17 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06499350 | A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 33 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06641609 | A Phase I Study of CFT8919 in Patients With Advanced NSCLC | recruiting | Phase 1 | 166 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07468851 | A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy | recruiting | Phase 1 / Phase 2 | 180 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07678970 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 10 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07718165 | A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 | 247 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 220 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04524871 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)(MORPHEUS-LIVER) | active not recruiting | Phase 1 / Phase 2 | 518 | Hoffmann-La RocheINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | recruiting | Phase 1 / Phase 2 | 160 | Sellas Life Sciences GroupINDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05518045 | A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 392 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05533775 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma(iMATRIX GLO) | recruiting | Phase 1 / Phase 2 | 65 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
Data updated 19 days agoSource updated unknownsource: clinicaltrials